Gilead Sciences, Inc.
10% Owner

Gilead Sciences, Inc. insider trades: Arcus Biosciences (RCUS) stock purchases

10% Owner, Arcus Biosciences Last trade Feb 18, 2025 16 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
9
Open-market trades
since 2021
6
Companies
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Gilead Sciences, Inc. reports to the SEC

Open-market buys and sales

9 trades reported on SEC Form 4, newest first

DateStockTypeValue
Feb 18, 2025RCUS↑ Buy$15.0M
Dec 19, 2024ASMB↑ Buy$20.1M
Dec 18, 2024XLO↑ Buy$1.8M
Apr 2, 2024XLO↑ Buy$369K
Feb 12, 2024KYTX↑ Buy$20.0M
Jan 29, 2024RCUS↑ Buy$320.0M
Jun 28, 2023RCUS↑ Buy$19.5M
Jun 27, 2023ALVR↑ Buy$11.0M
Jan 31, 2021RCUS↑ Buy$220.3M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other RCUS insiders

Open-market trades in the last 12 months

About Gilead Sciences, Inc.'s insider trades

Gilead Sciences, Inc. is a 10% owner of Arcus Biosciences (RCUS). Since Jan 31, 2021, it has reported 9 open-market purchases worth $628.1M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Its filings also include other transactions (6 filings), conversions (2 filings), grants and awards (1 filing), option exercises (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RCUS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.